Regeneron Reports Fianlimab plus Libtayo Showed Above 60% Response Rate in Patients with Advanced Melanoma Naïve to PD-1 or PD-L1 Inhibitors
(NEWS PROVIDED BY Regeneron Pharmaceuticals, Inc. Sep 12, 2022, 02:30 ET) Positive clinical data presented in a mini-oral session at ESMO…